Abstract:The discovery that subanesthetic doses of (R, S)-ketamine (ketamine) and (S)-ketamine (esketamine) rapidly induce antidepressant effects and promote sustained actions following drug clearance in depressed patients who are treatment-resistant to other therapies has resulted in a paradigm shift in the conceptualization of how rapidly and effectively depression can be treated. Consequently, the mechanism(s) that next generation antidepressants may engage to improve pathophysiology and resultant symptomology are being reconceptualized. Impaired excitatory glutamatergic synapses in mood-regulating circuits are likely a substantial contributor to the pathophysiology of depression. Metaplasticity is the process of regulating future capacity for plasticity by priming neurons with a stimulation that alters later neuronal plasticity responses. Accordingly, the development of treatment modalities that specifically modulate the duration, direction, or magnitude of glutamatergic synaptic plasticity events such as long-term potentiation (LTP), defined here as metaplastogens, may be an effective approach to reverse the pathophysiology underlying depression and improve depression symptoms. We review evidence that the initiating mechanisms of pharmacologically diverse rapid-acting antidepressants (i.e., ketamine mimetics) converge on consistent downstream molecular mediators that facilitate the expression/maintenance of increased synaptic strength and resultant persisting antidepressant effects. Specifically, while the initiating mechanisms of these therapies may differ (e.g., cell type-specificity, N-methyl-D-aspartate receptor (NMDAR) subtype-selective inhibition vs activation, metabotropic glutamate receptor 2/3 antagonism, AMPA receptor potentiation, 5-HT receptor-activating psychedelics, etc.), the sustained therapeutic mechanisms of putative rapid-acting antidepressants will be mediated, in part, by metaplastic effects that converge on consistent molecular mediators to enhance excitatory neurotransmission and altered capacity for synaptic plasticity. We conclude that the convergence of these therapeutic mechanisms provides the opportunity for metaplasticity processes to be harnessed as a druggable plasticity mechanism by next-generation therapeutics. Further, targeting metaplastic mechanisms presents therapeutic advantages including decreased dosing frequency and associated diminished adverse responses by eliminating the requirement for the drug to be continuously present.

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression

Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression

Targeting the dysfunction of glutamate receptors for the development of novel antidepressants

Glutamatergic Modulators for Major Depression from Theory to Clinical Use

Drugs with glutamate-based mechanisms of action in psychiatry

GluN2A: A Promising Target for Developing Novel Antidepressants

Potential Anti-Depressive Treatment Maneuvers from Bench to Bedside.

Development of Antidepressant Drugs Through Targeting Α4β2-Nicotinic Acetylcholine Receptors

Profiling the Structural Determinants of Aryl Benzamide Derivatives As Negative Allosteric Modulators of Mglur5 by in Silico Study

Update on GPCR-based targets for the development of novel antidepressants

A brief history of the development of antidepressant drugs: From monoamines to glutamate.

Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors

Targeting metaplasticity mechanisms to promote sustained antidepressant actions

Targeting of NMDA Receptors in the Treatment of Major Depression.

Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions

Discovery of Novel and Potent <i>N</i>-Methyl-D-aspartate Receptor Positive Allosteric Modulators with Antidepressant-like Activity in Rodent Models